Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset, a drug for ulcerative colitis, that showed a potential cancer risk in patients.
The medicine met its endpoints of demonstrating a clinically meaningful efficacy and a remission rate of about 40% for both doses tested, but also showed there were three cancer cases among patients taking the higher dose.
“[The] cancer signal complicates matters,” a Jefferies analyst said. “Even if unrelated noise, we think the overhang will be real, especially considering absence of other value-inflecting data events over the next [year].”
This is breaking news. Please refresh for updates.
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update NYT News Today.
Hence then, the article about biotech takeover target abivax sinks over 30 after bowel disease drug trial update was published today ( ) and is available on NY Times News ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update )
Also on site :
- ‘You’re f***ing crazy!’ Trump yelled at Netanyahu for derailing Iran talks – Axios
- Hackers Tricked Meta AI Into Handing Out Access to Major Instagram Accounts
- Report: Trump upbraids Netanyahu over Lebanon, asking, 'What the f--- are you doing?'